---
title: "China's first stem cell therapy drug is on the market! Multiple listed companies respond"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/223869707.md"
description: "Today, stem cell concept stocks opened with fluctuations. On the news front, on January 2nd, the National Medical Products Administration conditionally approved the listing of the first stem cell therapy drug in China, Aimi Maitosai Injection, through a priority review and approval process, for the treatment of acute graft-versus-host disease (aGVHD) primarily affecting the digestive tract in patients over 14 years old who have failed hormone therapy. In this regard, reporters contacted Zhongyuan Union, Guanhao Biotech, and Landfar Bio-medicine regarding their stem cell business. Staff from Guanhao Biotech and Landfar Bio-medicine stated that the company mainly involves stem cell storage and currently has no stem cell therapy drugs"
datetime: "2025-01-03T03:37:27.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/223869707.md)
  - [en](https://longbridge.com/en/news/223869707.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/223869707.md)
generator: "portal-rs"
---

# China's first stem cell therapy drug is on the market! Multiple listed companies respond

On January 3rd, Jinshi Data reported that today, stem cell concept stocks opened with fluctuations. In terms of news, on January 2nd, the National Medical Products Administration conditionally approved the listing of the first stem cell therapy drug in China, Aimi Maitosai Injection, through a priority review and approval process, for the treatment of acute graft-versus-host disease (aGVHD) primarily affecting the gastrointestinal tract in patients over 14 years old who have failed hormone therapy. In this regard, reporters contacted Zhongyuan Union, Guanhao Biotech, and Landfar Bio-medicine regarding their stem cell business. Staff from Guanhao Biotech and Landfar Bio-medicine stated that the company mainly involves stem cell storage and currently does not have stem cell therapy drugs

### Related Stocks

- [000504.CN](https://longbridge.com/en/quote/000504.CN.md)
- [300238.CN](https://longbridge.com/en/quote/300238.CN.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)
- [600645.CN](https://longbridge.com/en/quote/600645.CN.md)
- [003020.CN](https://longbridge.com/en/quote/003020.CN.md)
- [02607.HK](https://longbridge.com/en/quote/02607.HK.md)
- [002826.CN](https://longbridge.com/en/quote/002826.CN.md)
- [02005.HK](https://longbridge.com/en/quote/02005.HK.md)
- [002728.CN](https://longbridge.com/en/quote/002728.CN.md)
- [600420.CN](https://longbridge.com/en/quote/600420.CN.md)
- [600056.CN](https://longbridge.com/en/quote/600056.CN.md)

## Related News & Research

- [China's Wang Yi invites South Korean national security adviser to China, Blue House says](https://longbridge.com/en/news/296462771.md)
- [EXCLUSIVE-Fauci's lawyers set up legal defense fund as US probes multiply](https://longbridge.com/en/news/296651059.md)
- [Percheron Therapeutics Corrects Auditor Report Omission in FY2026 Annual Filing](https://longbridge.com/en/news/296318843.md)
- [08:46 ETO'Shaughnessy Ventures Backs Scientist's Bid to Prevent Tick Bites](https://longbridge.com/en/news/296493849.md)
- [Motor racing-Verstappen commits to Red Bull until end of 2030](https://longbridge.com/en/news/296454611.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**